Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.
April Rieger2023-12-14T13:11:11-05:00July 30th, 2015|Categories: Blog|Tags: benchmark reports, comparative effectiveness, Cost Effectiveness Analysis, Dan Ollendorf, Emerging Therapy Assessment and Pricing, evidence-based medicine, Health Economic Models, health outcomes models, ICER, Institute for Clinical and Economic Review, Patti Peeples, Pharmaceutical Industry, real world evidence, Steve Pearson, tHEORetically Speaking|
Swarali Tadwalker, MPH Hardly a day goes by without a new article being published in the mainstream press [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Practical AI: Adding Insight to the Patient Journey with Digital Phenotyping
Thursday, May 23, 2024
Sponsor: OM1
Insights from the 2024 Salary Survey Report by HealthEconomics.com
Wednesday, May 1, 2024
Webinar Host: Scientist.com
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
HEOR
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Press Release
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication